Gilead said the FDA accepted its supplemental New Drug Application for Yeztugo (lenacapavir) 300-mg tablets as a potential once-weekly oral pre-exposure prophylaxis (PrEP) option. The agency assigned a PDUFA action date of February 2, 2027, setting a defined regulatory timeline for the first long-acting oral pill intended to prevent HIV infection. The filing reflects a broader effort to move beyond traditional daily PrEP regimens by improving adherence and lowering dosing burden. Lenacapavir, previously known for its role in HIV treatment strategies, is now being positioned for prevention in a weekly, tablet-based format. For biotech and pharma, the decision will be watched as a signal on how regulators evaluate long-acting prevention approaches, including the clinical endpoints and durability of effect needed to support a first-in-class schedule and formulation.